Identification of differentially expressed genes in MG63 osteosarcoma cells with drug‑resistance by microarray analysis

Chen,Rui; Huang,Li‑Hong; Gao,Yi‑Yao; Yang,Jian‑Zeng; Wang,Yan

doi:10.3892/mmr.2018.9774

Identification of differentially expressed genes in MG63 osteosarcoma cells with drug‑resistance by microarray analysis

Authors:
- Rui Chen
- Li‑Hong Huang
- Yi‑Yao Gao
- Jian‑Zeng Yang
- Yan Wang
View Affiliations

Affiliations: Department of Nuclear Medicine; Changhai Hospital of Shanghai, Shanghai 200433, P.R. China, Geriatric Department, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Science Research Center, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 13003, P.R. China, Henan Medical Key Laboratory of Molecular Imaging, Nuclear Medicine Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China
Published online on: December 18, 2018 https://doi.org/10.3892/mmr.2018.9774
Pages: 1571-1580
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most common type of primary malignant bone tumor, with extremely poor prognosis in patients with metastatic disease and resistance to therapy, such as multidrug regimens. The mechanisms of drug resistance are quite complex and have not been fully elucidated; thus, novel therapeutic targets should be identified to alleviate drug resistance in osteosarcoma. In the present study, the transcriptomes of the human osteosarcoma cell line MG63 and vincristine (VCR)‑resistant MG63 cells were compared by microarray analysis. A total of 1,300 genes (602 upregulated and 698 downregulated) were reported to be differentially expressed in MG63/VCR compared with MG63 cells. Bioinformatics analysis predicted that the differentially expressed genes were mainly enriched in the B cell receptor, UVA‑induced mitogen‑activated protein kinases and receptor tyrosine kinase 2/3 signaling pathways. In the present study, 10 of the dysregulated genes, including roundabout homolog 1, death‑associated protein kinase 1 and A‑kinase anchor protein 12 were further evaluated by reverse transcription‑quantitative polymerase chain reaction. These results may aid the validation of candidate biomarkers for the treatment and prognosis of osteosarcoma, and provide novel insight into the molecular mechanisms underlying the drug resistance of osteosarcoma cells.

View Figures

View References

1	Cai S, Zhang T, Zhang D, Qiu G and Liu Y: Volume-sensitive chloride channels are involved in cisplatin treatment of osteosarcoma. Mol Med Rep. 11:2465–2470. 2015. View Article : Google Scholar : PubMed/NCBI
2	Zhang Y, Zhang L, Zhang G, Li S, Duan J, Cheng J, Ding G, Zhou C, Zhang J, Luo P, et al: Osteosarcoma metastasis: Prospective role of ezrin. Tumor Biol. 35:5055–5059. 2014. View Article : Google Scholar
3	Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
4	Wang Y and Teng JS: Increased multi-drug resistance and reduced apoptosis in osteosarcoma side population cells are crucial factors for tumor recurrence. Exp Ther Med. 12:81–86. 2016. View Article : Google Scholar : PubMed/NCBI
5	Wang X, Zheng H, Shou T, Tang C, Miao K and Wang P: Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: A network meta-analysis of randomized controlled trials. J Orthop Surg Res. 12:522017. View Article : Google Scholar : PubMed/NCBI
6	Hattinger CM, Pasello M, Ferrari S, Picci P and Serra M: Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs. 15:615–634. 2010. View Article : Google Scholar : PubMed/NCBI
7	Chou AJ and Gorlick R: Chemotherapy resistance in osteosarcoma: Current challenges and future directions. Expert Rev Anticancer Ther. 6:1075–1085. 2016. View Article : Google Scholar
8	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
9	Brasseur K, Gévry N and Asselin E: Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget. 8:4008–4042. 2017. View Article : Google Scholar : PubMed/NCBI
10	Lu C and Shervington A: Chemoresistance in gliomas. Mol Cell Biochem. 312:71–80. 2008. View Article : Google Scholar : PubMed/NCBI
11	Yang JZ, Ma SR, Rong XL, Zhu MJ, Ji QY, Meng LJ, Gao YY, Yang YD and Wang Y: Characterization of multidrug-resistant osteosarcoma sublines and the molecular mechanisms of resistance. Mol Med Rep. 14:3269–3276. 2016. View Article : Google Scholar : PubMed/NCBI
12	Felciano RM, Bavari S, Richards DR, Billaud JN, Warren T, Panchal R and Krämer A: Predictive systems biology approach to broad-spectrum, host-directed drug target discovery in infectious diseases. Pac Symp Biocomput. 17–28. 2013.PubMed/NCBI
13	Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, et al: A network-based analysis of systemic inflammation in humans. Nature. 437:1032–1037. 2013. View Article : Google Scholar
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Wang Z, Xia Q, Cui J, Diao Y and Li J: Reversion of P-glycoprotein-mediated multidrug resistance by diallyl trisulfide in a human osteosarcoma cell line. Oncol Rep. 31:2720–2726. 2014. View Article : Google Scholar : PubMed/NCBI
16	Tahara T, Arisawa T, Shibata T, Hirata I and Nakano H: Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. J Gastroenterol Hepatol. 22:1678–1682. 2007. View Article : Google Scholar : PubMed/NCBI
17	Zhou R, Huang W, Yao Y, Wang Y, Li Z, Shao B, Zhong J, Tang M, Liang S, Zhao X, et al: CA II, a potential biomarker by proteomic analysis, exerts significant inhibitory effect on the growth of colorectal cancer cells. Int J Oncol. 43:611–621. 2013. View Article : Google Scholar : PubMed/NCBI
18	Faye MD, Beug ST, Graber TE, Earl N, Xiang X, Wild B, Langlois S, Michaud J, Cowan KN, Korneluk RG and Holcik M: IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1. Oncogene. 34:1532–1541. 2015. View Article : Google Scholar : PubMed/NCBI
19	Xie XQ, Zhao QH, Wang H and Gu KS: Dysregulation of mRNA profile in cisplatin-resistant gastric cancer cell line SGC7901. World J Gastroentero. 23:1189–1202. 2017. View Article : Google Scholar
20	Chiang YC, Lin HW, Chang CF, Chang MC, Fu CF, Chen TC, Hsieh SF, Chen CA and Cheng WF: Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma. Oncotarget. 6:39740–39755. 2015. View Article : Google Scholar : PubMed/NCBI
21	Januchowski R, Świerczewska M, Sterzyńska K, Wojtowicz K, Nowicki M and Zabel M: Increased expression of several collagen genes is associated with drug resistance in ovarian cancer cell lines. J Cancer. 7:1295–1310. 2016. View Article : Google Scholar : PubMed/NCBI
22	Yuan J, Yin Z, Tao K, Wang G and Gao J: Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy. Oncol Lett. 15:41–47. 2018.PubMed/NCBI
23	Spaargaren M, Beuling EA, Rurup ML, Meijer HP, Klok MD, Middendorp S, Hendriks RW and Pals ST: The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med. 198:1539–1550. 2003. View Article : Google Scholar : PubMed/NCBI
24	Liu W, Barnette AR, Andreansky S and Landgraf R: ERBB2 overexpression establishes ERBB3-dependent hypersensitivity of breast cancer cells to withaferin A. Mol Cancer Ther. 15:2750–2757. 2016. View Article : Google Scholar : PubMed/NCBI
25	Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF and Collins VP: Genes for epidermal growth factor receptor, transforming growth factor, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 51:2164–2172. 1991.PubMed/NCBI
26	Suh KJ, Sung JH, Kim JW, Han SH, Lee HS, Min A, Kang MH, Kim JE, Kim JW, Kim SH, et al: EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. Oncotarget. 8:63901–63910. 2017. View Article : Google Scholar : PubMed/NCBI